Requirements for generic anti-epileptic medicines: a regulatory perspective. - Wikidata - awgldk - TriplyDB

Requirements for generic anti-epileptic medicines: a regulatory perspective.

Requirements for generic anti-epileptic medicines: a regulatory perspective.

http://www.wikidata.org/entity/Q37428755

about

Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs Interchangeability of gabapentin generic formulations in the Netherlands: a comparative bioavailability study.

P2860

Q26824723-07A1EA1E-1846-4659-A446-226ABCF2B450 Q45897472-320EACE8-1C78-470D-A74B-9091958BEC37

P2860

Requirements for generic anti-epileptic medicines: a regulatory perspective.

http://www.wikidata.org/entity/Q37428755

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Requirements for generic anti-epileptic medicines: a regulatory perspective.

@en

Requirements for generic anti-epileptic medicines: a regulatory perspective.

@nl

type

label

Requirements for generic anti-epileptic medicines: a regulatory perspective.

@en

Requirements for generic anti-epileptic medicines: a regulatory perspective.

@nl

prefLabel

Requirements for generic anti-epileptic medicines: a regulatory perspective.

@en

Requirements for generic anti-epileptic medicines: a regulatory perspective.

@nl

P1433

Q37428755-30DE3FF9-F449-4D06-99D5-17F979F313B2

P1476

Q37428755-C7F4B184-5C58-4EE1-8828-01C1B713A19D

P2093

Q37428755-2633878C-1305-4835-8B70-F2DA36018C11

Q37428755-45BC70DB-0AE8-4D81-9F48-1F2084AECCB3

Q37428755-71D64660-4E6F-4C83-98A7-E9FC074F1F0C

Q37428755-C3CF2068-260C-4160-A57A-E3B2E61CDE05

Q37428755-E36624D3-5BC1-4A1B-A07E-608F993C607B

Q37428755-E7092597-7B25-42B3-AC9D-FF842C045E7E

Q37428755-F2EBBB08-15A3-4259-B8C0-F34A489025E8

Q37428755-FAA8F0B9-9218-4D1F-BCA7-C61833CA6FB2

P2860

Q37428755-09438EFB-16DA-442A-AFBC-254F0E7BB375

Q37428755-305BBFFC-4667-4B8F-B807-29AE905E5C2B

Q37428755-443411E9-2D7F-4797-8445-DFE1CB7D7FE1

Q37428755-56AA9FF7-254A-4824-A28C-8A4E135AB6D0

Q37428755-684B5568-43A5-44B2-A4D7-2225CA3699F4

Q37428755-7604E76A-4AD3-42BD-A6B5-180B05B96669

Q37428755-798D3354-D0E5-4C22-BAC0-3606F5ABB7C8

Q37428755-8E915AD8-8E81-4048-BE64-22F5A0CF5CC0

Q37428755-8FC8D84E-C18A-4CB9-9CA0-439B3501D371

Q37428755-CA456FA3-6084-4263-AD2A-6D894C400412

P2888

Q37428755-A2762480-6F7F-40FF-95D9-341CCADDBA82

P304

Q37428755-C5F1F487-5A47-47A3-964C-6ECE7AD667F2

P31

Q37428755-C890E6EB-EF5B-461E-B5A4-9ACE53FE69D6

Q37428755-E418F6F0-6155-4990-8292-4606DACB8047

P356

Q37428755-FB00A880-1077-490A-9188-2A644F53D7BD

P433

Q37428755-55356CDC-ED0E-46D3-9851-63239F8B1DF3

P478

Q37428755-D1E3019D-9406-400A-A457-E3AF174FE471

P577

Q37428755-2F24C451-A8A5-4903-B75D-F3A086C87F27

Q37428755-DBB9AD0F-7550-4D67-B27A-5D02AB1D957D

P5875

Q37428755-48FB2105-F160-4C7B-93B1-A0B2F44E9AB2

P698

Q37428755-FFFBC489-8DA3-400A-AC97-4F8A7D09774A

P921

Q37428755-4069BEBE-FF08-451F-8EC2-B23DA00CA713

Q37428755-58B8FDEB-8852-4227-96E2-AD95217A356B

Q37428755-A68357EC-2F14-409C-9A60-E97D95A5738F

P932

Q37428755-5E3C4136-B600-47F9-AF7C-50485EB22620

P356

S00415-009-5231-2

P1433

Journal of Neurology

P1476

Requirements for generic anti-epileptic medicines: a regulatory perspective.

@en

P2093

André J Elferink

http://www.w3.org/2001/XMLSchema#string

Arnoud Kappelle

http://www.w3.org/2001/XMLSchema#string

Christine C Gispen-de Wied

http://www.w3.org/2001/XMLSchema#string

Eugène P van Puijenbroek

http://www.w3.org/2001/XMLSchema#string

Frits J F Lekkerkerker

http://www.w3.org/2001/XMLSchema#string

Jan Welink

http://www.w3.org/2001/XMLSchema#string

Marc Maliepaard

http://www.w3.org/2001/XMLSchema#string

Yechiel A Hekster

http://www.w3.org/2001/XMLSchema#string

P2860

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

The importance of drug interactions in epilepsy therapy.

Are there potential problems with generic substitution of antiepileptic drugs? A review of issues.

Antiepileptic drugs: generic versus branded treatments.

Lamotrigine plasma levels reduced by oral contraceptives.

Changes in medication associated with epilepsy-related hospitalisation: a case-crossover study.

Lamotrigine clearance during pregnancy.

Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.

The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases.

Oral contraceptives reduce lamotrigine plasma levels.

P2888

s00415-009-5231-2

P304

1966-1971

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00415-009-5231-2

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

256

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26671811

http://www.w3.org/2001/XMLSchema#string

P698

19603244

http://www.w3.org/2001/XMLSchema#string

P921

pharmaceutical preparation

P932

2780669

http://www.w3.org/2001/XMLSchema#string